World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
73
Citations
18887
World Ranking
5941
National Ranking
2812

Chemistry

D-Index
69
Citations
17714
World Ranking
6163
National Ranking
1874

Andrew D. Mesecar publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Andrew D. Mesecar sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 247 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Andrew D. Mesecar D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew D. Mesecar sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 73 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Andrew D. Mesecar is affiliated with Purdue University West Lafayette in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a significant focus on Molecular Biology and Infectious Diseases, complemented by work in Computational Theory and Mathematics, Physiology, and Spectroscopy.

Key topics central to their research include:

  • SARS-CoV-2 and COVID-19 Research
  • Computational Drug Discovery Methods
  • COVID-19 Clinical Research Studies
  • Alzheimer's disease research and treatments
  • Protein Tyrosine Phosphatases
  • RNA modifications and cancer
  • Endoplasmic Reticulum Stress and Disease

Andrew D. Mesecar has contributed to numerous publications featured in various scientific venues. Frequent publication platforms include:

  • Zenodo (CERN European Organization for Nuclear Research)
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Alzheimer's & Dementia
  • Biophysical Journal
  • UNC Libraries

Among recent papers authored or co-authored are:

  • "Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing", 2020, Nature
  • "Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics", 2020, ChemMedChem
  • "Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19", 2021, Nature Communications
  • "A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication", 2021, Nature Communications
  • "Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19", 2020, bioRxiv (Cold Spring Harbor Laboratory)

Frequent co-authors involved in the research efforts alongside Andrew D. Mesecar include:

  • Emma K. Lendy
  • Karson S. Putt
  • Brent Clayton
  • Arun K. Ghosh
  • Ramya Visvanathan

Best Publications

  • The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.

    Yahira M. Báez-Santos;Sarah E. St. John;Andrew D. Mesecar

  • Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.

    Laura Riva;Shuofeng Yuan;Xin Yin;Laura Martin-Sancho

  • The Papain-Like Protease of Severe Acute Respiratory Syndrome Coronavirus Has Deubiquitinating Activity

    Naina Barretto;Dalia Jukneliene;Kiira M. Ratia;Zhongbin Chen

  • Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis.

    Jill D. Dombrauckas;Bernard D. Santarsiero;Andrew D. Mesecar

  • Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2

    Aimee L. Eggler;Guowen Liu;John M. Pezzuto;Richard B. van Breemen

  • A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication

    Kiira Ratia;Scott Pegan;Jun Takayama;Katrina Sleeman

  • The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate.

    Melissa S Jurica;Andrew Mesecar;Patrick J Heath;Wuxian Shi

  • Severe acute respiratory syndrome coronavirus papain-like protease: Structure of a viral deubiquitinating enzyme

    Kiira Ratia;Kumar Singh Saikatendu;Bernard D. Santarsiero;Naina Barretto

  • Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease Ubiquitin-Like Domain and Catalytic Domain Regulate Antagonism of IRF3 and NF-κB Signaling

    Matthew Frieman;Kiira M. Ratia;Robert E. Johnston;Andrew D. Mesecar

  • Phosphorylation of Serine 256 Suppresses Transactivation by FKHR (FOXO1) by Multiple Mechanisms DIRECT AND INDIRECT EFFECTS ON NUCLEAR/CYTOPLASMIC SHUTTLING AND DNA BINDING

    Xiaohui Zhang;Lixia Gan;Haiyun Pan;Shaodong Guo

  • Deubiquitinating and Interferon Antagonism Activities of Coronavirus Papain-Like Proteases

    Mark A. Clementz;Zhongbin Chen;Bridget S. Banach;Yanhua Wang

  • Modification of keap1 cysteine residues by sulforaphane.

    Chenqi Hu;Aimee L. Eggler;Andrew D. Mesecar;Richard B. van Breemen

  • Molecular mechanisms of natural products in chemoprevention: induction of cytoprotective enzymes by Nrf2.

    Aimee L. Eggler;Andrew D. Mesecar

  • Xanthohumol isolated from Humulus lupulus Inhibits menadione-induced DNA damage through induction of quinone reductase.

    Birgit M. Dietz;Young Hwa Kang;Guowen Liu;Aimee L. Eggler

  • Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor.

    Joanna E Burdette;Jianghua Liu;Shao-Nong Chen;Daniel S Fabricant

  • Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics.

    Arun K. Ghosh;Margherita Brindisi;Margherita Brindisi;Dana Shahabi;Mackenzie E. Chapman

  • Orbital steering in the catalytic power of enzymes: small structural changes with large catalytic consequences.

    Andrew D. Mesecar;Barry L. Stoddard;Daniel E. Koshland

  • Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19.

    Britton Boras;Rhys M Jones;Brandon J Anson;Dan Arenson

  • New Chemical Constituents of Euphorbia quinquecostata and Absolute Configuration Assignment by a Convenient Mosher Ester Procedure Carried Out in NMR Tubes

    Bao Ning Su;Eun Jung Park;Zakaria H. Mbwambo;Bernard D. Santarsiero

  • Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris.

    Bang Yeon Hwang;Bao Ning Su;Heebyung Chai;Qiuwen Mi

  • X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases

    Yahira M. Báez-Santos;Scott J. Barraza;Michael W. Wilson;Michael P. Agius

Frequent Co-Authors

Bernard D. Santarsiero
Bernard D. Santarsiero University of Illinois at Chicago
Susan C. Baker
Susan C. Baker Loyola University Chicago
John M. Pezzuto
John M. Pezzuto Western New England University
Arun K. Ghosh
Arun K. Ghosh Purdue University West Lafayette
Richard B. van Breemen
Richard B. van Breemen Oregon State University
Harry H. S. Fong
Harry H. S. Fong University of Illinois at Chicago
A. Douglas Kinghorn
A. Douglas Kinghorn The Ohio State University
Jordan Tang
Jordan Tang Oklahoma Medical Research Foundation
Norman R. Farnsworth
Norman R. Farnsworth University of Illinois at Chicago
Daniel E. Koshland
Daniel E. Koshland University of California, Berkeley

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Andrew D. Mesecar

Trending Scientists

Recently Published Articles